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Abstract  
Current understanding of how platelets localise coagulation to wound sites has come mainly from 
studies of a subpopulation of activated platelets. In this review we summarise data from the last 
four decades which has described these platelets with a range of descriptive titles and attributes. 
We identify striking overlaps in the reported characteristics of these platelets which imply a single 
subpopulation of versatile platelets, and thus suggest that their commonality requires unification 
of their description. We therefore propose the term procoagulant platelet as the unifying 
terminology.  We discuss the agonist requirements and molecular drivers for the dramatic 
morphological transformation platelets undergo when becoming procoagulant. Finally, we provide 
perspectives on the biomarker potential of procoagulant platelets for thrombotic events, as well 
as on the possible clinical benefits of inhibitors of carbonic anhydrase enzymes and the water 
channel Aquaporin-1 for targeting this subpopulation of platelets as antiprocoagulant 
antithrombotics.   
 
 
Running title:   Unifying review of procoagulant platelets 
 
Keywords: ballooning, procoagulant platelets, mitochondrial permeability, procoagulant-
spreading. 
Acronyms/abbreviations: BNS, BAPS, Fib-Cap, MPTP, ROS, PS, NADPH 
ADP: Adenosine diphosphate 
vWF: Von Willebrand factor 
GSAO: 4-[N-(S-glutathionylacetyl) amino] phenylarsonous acid  
SCIP: Sustained Calcium Induced Platelets 
BAPS: Ballooned And Procoagulant-Spread  
BP: Ballooned Platelets 
BNS: Ballooned Non Spread 
PS: Phosphatidylserine 
FIB-CAP: Fibrinogen Capped Platelets  
MPTP: Mitochondrial Permeability Transition Pore  
HDBS: High Density Bubble Shaped  
COATED: Collagen And Thrombin Activated  
ROS: Reactive Oxygen Species 
NADPH: Nicotinamide Adenine Dinucleotide Phosphate 
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1. Introduction 
The ability of platelets to multitask is critical to the arrest of bleeding after injury, and to the 
development of arterial thrombosis, which underlies stroke and coronary artery disease. Following 
the reflex vasoconstriction of an injured vessel, platelets are recruited to the wound site to which 
they adhere and aggregate to form a fragile plug in the initiation of haemostasis. Platelets then 
provide the requisite membrane for the assembly of the prothrombinase complex, thereby 
localising coagulation to the wound site. The local generation of thrombin catalyses the conversion 
of soluble fibrinogen to insoluble fibrin, which stabilises the plug into a firm clot that prevents 
bleeding and promotes healing. It is now apparent that different populations of platelets play 
different roles in the cascade of events in thrombus formation. 
 
The concept of functionally different subpopulations of platelets or division of labour amongst 
platelets at wound sites is well reported. For example, Patel et al.,1 described differences between 
‘vanguard platelets’, a subpopulation that is the first to adhere to collagen and a second population 
of ‘follower platelets’ that adhere over the top of these. Furthermore, it is now well accepted that 
even after strong activation, not all stimulated platelets become procoagulant.  Accordingly, 
differential expression on the plasma membrane of phosphatidylserine (PS) or components of the 
prothrombinase complex have been reported after platelet activation with thrombin and/or 
collagen2,3 (see Fig. 1). Indeed, an increasing number of studies show heterogeneity in platelet 
responses to agonists. Two distinct phenotypes are discernible in the literature, a procoagulant 
phenotype which externalises phosphatidylserine, binds tenase and prothrombinase complexes 
and accelerates coagulation at the wound site and an aggregating and contractile phenotype 
characterised by active integrin αIIbβ3 which pulls fibrin over the platelet plug to tighten the clot 
into an impermeable cell mass4-7.  
 
Over the last four decades, several subpopulations of platelets with different features have been 
identified, named and suggested as candidates for the procoagulant platelet. In this review we 
summarise these data, reveal attributes central to these platelet phenotypes and provide 
perspectives on the mechanisms and molecular targets in the procoagulant response of activated 
platelets. We suggest that the various phenotypes described actually form a spectrum of a single 
platelet phenotype, the procoagulant platelet.  Finally, we examine the potential for targeting this 
platelet subpopulation as an antithrombotic approach. In this regard we discuss the potential of 
inhibitors of the water channel aquaporin-1 (AQP1) and the repurposing of carbonic anhydrase 
inhibitors as antiprocoagulant antithrombotics, which may selectively limit the platelet 
procoagulant responses while sparing platelet aggregation and secretion. 
 
1.1          How one platelet becomes procoagulant whilst another does not 
A high and sustained calcium rise is required for PS externalisation, coagulation factor binding and 
calpain-mediated inactivation of αIIbβ3 integrin, and is a major difference between aggregatory and 
procoagulant platelets, possibly explaining their different derivations8-11.  It is well known that the 
procoagulant response of strongly activated platelets is preceded by calcium mobilisation from 
intracellular stores10,12,13; this is associated with the activation of Ca2+ activated chloride channels, 
resulting in an initial salt entry which is then followed by the influx of water8. The chloride ion entry 
causes membrane hyperpolarisation and enhances the electrochemical drive for Ca2+ entry14 
through both store-operated and store-independent pathways; together these ensure a high and 
sustained level of cytosolic calcium required to drive the procoagulant response8,10,12-14. The 
pattern of calcium signalling is different in adherent aggregating platelets, which are rather 
characterised by intermittent spikes in calcium levels or oscillatory calcium responses and the 
sustained engagement of αIIbβ3 integrins8,10,15,16. Furthermore, platelet age or level of oxidative 
stress may pre-commit platelets to aggregatory or procoagulant phenotypes as discussed later in 
this review.  
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2. Categorisation of procoagulant platelet types 
Platelets reported in the literature to be procoagulant show several overlapping features, and may 
be classified as ballooning or MPTP phenotypes based on the broad descriptions provided in the 
corresponding papers here reviewed. We depict the features of these platelets, and explain their 
overlaps.  
  
Figure 1: Procoagulant attributes and causative mechanisms of candidate procoagulant platelets. Figure shows 
platelet phenotypes by their published names or by their unique features as follows: 1)-(BP/BNS)8,10,17: Ballooned 
Platelets/Ballooned Non-Spread Platelets, 2)-(SCIP)17: Sustained Calcium-Induced Platelets, 3)-(BAPS)8,18: Ballooned 
And Procoagulant-Spread platelets8; High Density Bubble Shaped (HDBS) platelets also show similar features19, 4)-(FIB-
CAP)20,21: Fibrinogen Capped platelets; characterised by PS exposure, the lack of active integrin αIIbβ3 and the retention 
of fibrinogen and thrombospondin as a single patch or cap on the procoagulant platelets. 5)-(GSAO)22,23:  4-[N-(S-
glutathionylacetyl) amino] phenylarsonic acid binding procoagulant platelets, 6)-(MPTP)24-28: procoagulant platelets 
dependent on the formation/opening of Mitochondrial Permeability Transition Pore and 7)-(COATED)11,26-30: COllagen 
And Thrombin-activated platelets. BP, SCIP, BAPS and FIB-CAP platelets are broadly referred to as 
ballooning/ballooned platelets; while GSAO, MPTP and COATED platelets are broadly classified as MPTP phenotype. 
The procoagulant attributes are qualitative features of procoagulant platelets which we scored 100 for ‘Yes’, 0 for ‘No’, 
and 50 for transient features or ‘Yes/No’. Features based on the ‘causative mechanisms’ are quantitative; for this we 
assigned values based on published fractional responses or the reported percentage procoagulant platelets formed. 
We then present these data as a colour map where the upper, middle and lower end of a 0 - 100 scale is represented 
by Red, Yellow and Blue, respectively. To determine the characteristic features of the procoagulant platelet based on 
pooled data, we used the mean value for each feature across candidates of the procoagulant platelet (BP, BNS, HDBS, 
FIB-CAP, SCIP, BAPS, GSAO, COATED & MPTP), as shown in the corresponding row of the ‘PROCOAG ID’ column. The 
colour map was generated using Prism 7 (GraphPad software). White spaces within map represent unknown 
parameters while the black column demarcates the individual scores from the mean score in the ‘PROCOAG ID’ 
column.  
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2.1 Balloon shaped or ballooning phenotypes  
The earliest report of a ballooning platelet phenotype was in 1978 by Wester et al., who reported 
the ultrastructural changes platelets undergo to arrest bleeding after skin vessel transection31,32. 
Changes in platelet morphology were investigated at high resolution by electron microscopy and a 
subset of platelets was observed to have assumed a ballooned shape, with fibrin deposited 
between platelet balloons. These ballooned platelets were an integral part of the platelet plug and 
stable clot 31,32. About two decades later, this phenotype was generated in vitro on a collagen 
matrix, and platelets shown to externalise PS after a sustained cytosolic calcium rise and in the 
presence of physiological levels of extracellular calcium10. Since then several studies have 
investigated the procoagulant attributes of this platelet phenotype and its contribution to arterial 
thrombus formation8,10,17,20,21,33,34. It is clear that ballooned platelets not only bind annexin-V as 
indication of PS exposure but provide an extended surface area for the assembly of the 
prothrombinase complex and contribute to the acceleration of coagulation at the wound 
site8,20,21,33,34. Ballooned phenotypes have been reported as either BP8,10,34, SCIP17, Fib-CAP20,21 or 
BAPS8 (Fig.1), and show attributes similar to other candidates of the ‘procoagulant platelet’ such 
as the MPTP and COATED platelets 29,35. 
 
2.2 Mitochondrial permeability transition pore (MPTP) phenotype  
In a recent study, Hua et al. showed that co-labelling of platelets with fluorescent conjugates of a 
tripeptide trivalent arsenical 4-[N-(S-glutathionylacetyl) amino] phenylarsonous acid (GSAO) and 
an α-granule marker identified a subpopulation of activated procoagulant platelets undergoing 
cyclophilin-D dependent necrosis22. GSAO likely covalently binds to proteins containing cysteine 
thiols36 as it has been previously reported to covalently bind the molecular chaperone heat shock 
protein 90 (Hsp90)37. We have previously shown that the actin cytoskeleton undergoes 
remodelling and the cell membrane increases permeability during platelet transformation to the 
procoagulant phenotype8, and this would allow GSAO to label intracellular proteins in necrotic 
platelets22.  Furthermore, GSAO platelets show striking similarities to the activated necrotic 
platelets described by Jobe et al.,24 as ‘highly activated platelets’, characterized by high-level PS 
externalization, high-level fibrinogen retention, antigenic modulation of αIIbβ3 and marked 
membrane vesiculation. Like GSAO platelets, the formation of this subpopulation of platelets was 
dependent on cyclophilin-D induced mitochondrial permeability transition pore (MPTP) formation 
and opening. Cyclophilin-D is considered a modulatory component of MPTP which may regulate 
pore opening to allow for cytosolic molecule influx, leading to increased matrix volume, disruption 
of mitochondrial outer membrane and oxidative stress38,39.  Accordingly, Cyclophilin-D inhibition 
(by Cyclosporin A, coenzyme Q, or bongkrekic acid) markedly reduced the formation of both MPTP 
and GSAO platelets in independent experiments22,24,26. Another platelet subpopulation exhibiting 
the MPTP phenotype is the COATED platelet.  These were originally so named by Dale in 2005, as 
a subpopulation of platelets that were generated after ‘CO’llagen ‘A’nd ‘T’hrombin stimulation27. 
Specific parameters characterize this PS exposing platelets, namely the surface expression of α-
granule proteins such as FVa, strong binding of transglutaminase substrates, fibrinogen, von 
Willebrand factor, thrombospondin, fibronectin and α2-antiplasmin27.  
 
2.3 Commonalities of candidate procoagulant platelets  
Like the ballooning phenotype of procoagulant platelets (BP, SCIP, BAPS, FIB-CAP), COATED 
platelets bind α-granule protein, fibrinogen 27,28, externalise PS28, promote microvesiculation30 and 
become membrane permeable after activation28. Furthermore, convincing data also indicate 
COATED platelet formation is associated with rapid loss of loss of mitochondrial transmembrane 
potential (Δψm)26, a characteristic also described for MPTP and GSAO platelets22,24. Other striking 
similarities in the formation and characteristics of the ‘procoagulant platelet’, as described in the 
literature, are shown in Fig. 1. The overlap in features of these platelets is therefore strongly 
suggestive of a single procoagulant versatile subpopulation of platelets. We therefore propose that 
platelets previously described by any of these range of descriptors, that show the common 
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characteristics indicated in the ‘PROCOAG-ID’ column of Fig. 1, be simply referred to as 
procoagulant platelets.  
 
The features of the procoagulant platelet have differed depending on whether it was investigated 
in suspension (COATED, MPTP, BNS, FIB-CAP or GSAO) or adherent to solid agonist-coated matrices 
(SCIP, MPTP, BNS, BAPS, FIB-CAP). Unlike in suspension, a solid matrix provides procoagulant 
platelets with an adhesion platform upon which unique morphological transformations can occur. 
Features such as procoagulant-spreading, observed in SCIP and BAPS platelets, have been 
identified after adhesion to agonist-coated surfaces8,17, but not in suspension.  The characteristics 
of the procoagulant platelet, identified under either adhesion or suspension conditions, are 
summarised in Table. 1.   
 
 
Table 1: Features of 
adherent and non-
adherent procoagulant 
platelets. Procoagulant 
platelets show similar 
features, in the presence of 
physiological 
concentrations of 
extracellular calcium, 
whether studied adherent 
to a collagen matrix or 
stimulated with collagen in 
suspension. A distinguishing 
feature, unique to adherent 
platelets, is the formation of 
procoagulant-spread structures. There are currently no identified features that suspended procoagulant platelets 
show that are unique to this mode of activation.  
 
 
3. Mechanisms of procoagulant platelet formation 
The seven candidates for the procoagulant platelet shown in Fig. 1 share a common mechanism of 
formation which we will now discuss; a further indication that these comprise a spectrum of a 
single platelet phenotype. 
 
3.1 Agonist requirement for procoagulant platelet formation 
Collagen remains the most important single agonist for the formation of adherent procoagulant 
platelets in the presence of physiological concentrations of extracellular calcium; it accounts for 
40-80% of the procoagulant platelets formed under this condition8,10 (Fig. 1). In suspension 
however, co-stimulation with agonists of protease-activated receptors was often necessary to 
achieve a similar size of procoagulant subpopulation22,24. With thrombin alone, the proportion of 
activated platelets that become procoagulant varied from 20-60% in suspended platelets to 1-30% 
in platelets adhered to inert surfaces (Fig. 1).These differences are likely to be due to variations in 
experimental conditions and to the different agonist stimulation pathways; however, in both 
adherent and suspended platelets, signalling via the glycoprotein VI (GPVI) receptor is a major 
pathway for the formation of procoagulant platelets. Platelet activation with adenosine 
diphosphate, von Willebrand factor,  or a thromboxane A2 mimetic alone does not or only weakly 
generates procoagulant platelets18. In addition, some studies report that platelet pre-treatment 
with aspirin has minimal effect on the generation of procoagulant platelets22,35.   
 
Adherent Platelets Suspended Platelets 
• PS exposing 
• FXa/ FVa binding 
• Thrombin generation 
• ↑_membrane permeability 
• Loss of Δψm 
• Mitochondrial depolarisation 
• Cyclophilin-D dependence 
• Microvesiculation 
• Ballooning 
• Procoagulant-Spreading 
 
• PS exposing 
• FXa/ FVa binding 
• Thrombin generation 
• ↑_membrane permeability 
• Loss of Δψm 
• Mitochondrial depolarisation 
• Cyclophilin-D dependence  
• Microvesiculation  
• Ballooning 
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3.2 Calcium dependence of procoagulant platelets 
Platelet activation via GPVI or Gq-coupled protease-activated receptors leads to a sustained 
increase in cytosolic calcium owing both to extracellular calcium influx and calcium mobilisation 
from stores12,40. The role of calcium signalling in the formation of procoagulant platelets is pivotal, 
as formation of these platelets is abrogated by the depletion of extracellular calcium or by BAPTA 
mediated chelation of cytosolic calcium8,10, (Fig. 1); notably, there needs to be a sustained rise in 
cytosolic calcium to activate downstream signalling for a procoagulant response8,10,21,22,41 (Fig. 1).  
 
3.3 The role of calpain 
Sustained elevated cytosolic calcium required for the procoagulant response will in tandem breach 
the threshold of [Ca2+]Cyt required to activate the thiol protease, calpain17,42.  Major contractile 
cytoskeletal and membrane linker proteins such as actin, vinculin and myosin have been identified 
as calpain substrates43. Once activated, calpain may induce the proteolysis of these proteins, and 
aid the remodelling associated with the dramatic transformation of the procoagulant platelet. The 
fragmentation of the procoagulant platelet membrane and eventual release of PS-positive 
microvesicles is consistent with calpain action44. Indeed, we recorded a rise in levels of activated 
calpain during active membrane ballooning in collagen activated platelets (Fig. 2) consistent with 
previous reports of calpain activation in collagen-stimulated platelets45,46. 
 
Figure 2: Spatio-temporal pattern of calpain activation, PS exposure and 
reactive oxygen species generation in the ballooning platelet. Extended 
focus images obtained at 20 min after platelet adherence to fibrillar 
collagen show the spatial location of exposed PS indicated in red (as 
monitored by membrane annexin-V accumulation), calpain indicated in 
cyan and reactive oxygen species (ROS) indicated in green. Calpain activity 
was monitored by the 7-Amino-4-chloromethylcoumarin (CMAC) based 
substrate, fluorogenic t-BOC-Leu-Met-CMAC substrate which yield 
fluorescent peptidase products with improved retention in live platelets.  
The generation of ROS during membrane ballooning was followed in real-
time by means of MitoSox™ (ThermoFisher Scientific), which is rapidly 
oxidized by superoxide to produce highly fluorescent products. Chart shows 
the temporal profile of calpain activation, PS exposure and ROS generation 
in a ballooning human platelet. Written informed consent was obtained in 
accordance with the Declaration of Helsinki. Human blood was obtained 
from healthy, drug-free volunteers under the University of Bristol, United Kingdom, Research Ethics approval (E5736). 
Live cell imaging was performed at 25 °C using a spinning-disk confocal system as previously described8,18. Scale bar 
represents 3 µm. Data are representative of 4 independent experiments. 
 
3.4 Integrin activation  
The structure and function of the platelet integrin αIIbβ3 is extensively reviewed elsewhere47,48. This 
integrin is the best characterised of the platelet integrins, yet reports of its role in the formation of 
procoagulant platelets are conflicting8,21,25. For example after collagen stimulation, the BAPS 
phenotype of platelets showed high fibrinogen binding and αIIbβ3 activation, however BP, COATED, 
SCIP, MPTP and FIB-CAP platelets vary in this respect9 (Fig. 1). Some of the discrepancies may result 
from differences in kinetics of integrin activation. Platelets stimulated with convulxin/thrombin 
showed high fibrin and fibrinogen binding, which was associated with decreased PAC-1 binding 
after an initial peak11; this supports previous reports of secondary inactivation of integrin αIIbβ39,17 
and a conclusion that its activity during the formation of procoagulant platelets is transient. 
Moreover, it is possible that fibrinogen and fibrin bind to distinct sites on integrin αIIbβ315,49-51, and 
binding to each may be modulated differently by the mechanisms of integrin inactivation.  
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3.5 Chloride ion (Cl-) entry and a role for TMEM16F 
Our pooled data indicate an association between the platelet procoagulant response and Cl- entry 
(Fig. 1); strong stimulation of platelets with collagen and or thrombin induce Cl- entry, which drives 
membrane hyperpolarisation and PS exposure14. There is also good evidence that TMEM16F or 
Ano6 is a key channel for Cl- entry in this response52,53. Indeed, ablation of TMEM16F54 or the 
blockade of calcium-activated Cl- channels with small molecule inhibitors markedly diminished the 
platelet procoagulant response8. Accordingly, membrane ballooning was ablated in the Scott 
patient’s platelets, thus indicating an important role for TMEM16F in the platelet procoagulant 
response8,9,53-57.   
 
3.6 The procoagulant platelet is under oxidative stress 
Independent of granular release, the oxidizing agent H2O2 alone can induce a cyclophilin-D 
dependent loss of mitochondrial transmembrane potential (Δψm) due to MPTP formation and 
opening24; this effect is calcium-independent and is mediated by thiol oxidation58,59. The pooled 
evidence (Fig. 1) indicates that thrombin alone is a weak agonist for inducing the procoagulant 
response in activated platelets; however once under oxidative stress, platelets are 6 times more 
likely to become procoagulant with thrombin stimulation alone24. This suggests a role for 
intracellular oxidative stress and reveals an ancillary pathway independent of strong stimulation 
for the formation of the ‘procoagulant platelet’. Interestingly, oxidative stress alone has been 
shown to have no effect on fibrinogen binding, PS externalization, or granule release, raising the 
possibility that intravascular oxidative stress may play a role only in the priming of platelets for 
procoagulant response. This fits the observation that platelet aging, which has been reported to 
be associated with glutathione peroxidase-1 or NADPH oxidase dysfunction and oxidative 
stress60,61 may also prime and commit platelets to the procoagulant pathway. Equally, drugs or 
oxidizing agents that potentiated platelet oxidative stress or MPTP formation/opening have been 
shown to promote the formation of procoagulant platelets24,26. Consistent with these and related 
findings previously reviewed60, we observed that the procoagulant response of human platelets 
adhering to collagen was associated with increased superoxide generation (Fig. 2).  
  
3.7        A phenotype that gains function by dying 
Although it is clear that procoagulant platelets are undergoing a death process, the literature is 
ambivalent on whether this is by apoptosis26,62 or necrosis8,22, indicating that the process may be 
strictly neither. Instead, it follows a pathway analogous to necrosis, but differentiated by a gain of 
procoagulant function. This pathway is induced by external ligand and characterised by the 
following features: (1) calcium dependence8,10,12,18 (2) cyclophilin-D and but not Bax/Bak ablation 
dependence22,24 (3) formation/opening of mitochondrial permeability transition pore24,58, (4) early 
and rapid loss of Δψm24,  (5) intracellular oxidative stress8,22,26, (6) membrane ballooning due to a 
tightly regulated fluid entry system8,10, (7) an early increase in membrane permeability associated 
with microtubule unwinding and (8) calpain mediated remodelling of the actin-cytoskeleton44,63. 
Characteristically, these events are caspase-independent (Fig. 1), yet they drive the amplification 
of thrombin generation through the combined increase in membrane PS exposure and membrane 
surface area and microvesiculation8,18,24. It is interesting to note, that while cell death is classically 
associated with a loss of function, for the procoagulant platelet the death process is clearly 
mechanistically important.   
 
3.8           The procoagulant response is regulated by fluid entry  
A key event during procoagulant platelet formation is the irreversible membrane swelling or 
ballooning which results from the physical disruption of the membrane-cytoskeleton interaction, 
and an increase in internal hydrostatic pressure provided by a coordinated fluid entry system8. 
Balloon formation is reported in adherent platelets8,18 as well as in stimulated platelet 
suspensions9,64; here in Fig. 3, we illustrate its formation mechanism. The fluid entry requirement 
for ballooning distinguishes this process from blebbing, which is the formation of retractable 
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membrane protrusions. Blebbing is often used interchangeably with ‘ballooning’10,65; whereas both 
events illustrated in Fig. 3 are distinct and driven by separate mechanisms8. For example, (i) 
balloons, but not transient membrane blebs, are procoagulant; (ii) ballooning but not bleb 
formation requires disruption to the platelet microtubule cytoskeleton and increased membrane 
permeability; (iii) unlike blebs, procoagulant ballooning is irreversible and consequent upon Na+, 
Cl- and water entry, and (iv) whereas the hydrostatic pressure required for bleb formation is fluid 
entry-independent, the rapid membrane expansion associated with ballooning requires fluid entry 
driven by the osmotic pressure of salt entry8 (Fig. 3). Precision is therefore required when 
discussing these events in platelets. 
Figure 3: Membrane blebbing and 
ballooning in human platelets. Membrane 
blebbing is initiated by localised cortical actin 
contraction66,  (A) which weakens the 
membrane-cytoskeleton interaction and 
allows internal hydrostatic pressure to drive 
membrane protrusions (< 1µm diameter). 
This may be accompanied by a further 
detachment of the membrane from the 
cortex and a total volume change of < 10% 
(B). The recruitment of myosin to the 
expanded cortex enables bleb retraction (C, 
D) 66,67. Blebs were shown to form at one or 
more sites on platelet membranes upon 
contact with collagen, and are retractable and may be re-formed8. At some point, usually a single bleb would undergo 
a rapid increase in volume resulting in a characteristic platelet balloon (E)8.  
 
4.0: Clinical relevance and translational potential for procoagulant platelets  
Globally, cardiovascular disorders (CVD) remain the largest single contributor to mortality and 
morbidity68,69.  The role of the procoagulant platelet in platelet-driven thrombosis may underlie 
this statistic. For example, on the one hand low levels of procoagulant platelets have been shown 
to correlate with increased frequency of acute ischemic stroke complications, especially after 
thrombolytic therapy and increased spontaneous intracranial haemorrhage70-72; and on the other, 
high levels of these platelets correlate with transient ischemic attack and stroke73,74 and with 
milder haemorrhagic phenotype in severe hemophilia75. It may therefore be possible to exploit 
procoagulant platelets either through targeting them pharmacologically or through identifying 
them as biomarkers, in the management of thrombotic cardiovascular disease. 
 
4.1        Procoagulant platelets as clinical biomarkers 
There is a need for universally accepted markers and/or identity criteria for the clinical assessment 
of thrombotic or bleeding tendency. It is possible that clinical markers could be designed based on 
the shared attributes of procoagulant platelets, and their identity criteria could be based on their 
commonalities shown in Fig. 1. For example, evaluation of blood from healthy donors for 
procoagulant platelets, based on the combined expression of activated coagulation proteins and 
PS externalisation, showed that about 31.67 ± 13.2% (mean± SD), of platelets can assume this 
phenotype after dual stimulation with collagen and thrombin as previously reported27,73. This 
figure varied widely between donors but appeared conserved within donors over time29, a clinical 
feature that may be exploited to individualise and monitor bleeding or thrombotic tendency in 
anticoagulation therapy or surgical units. Furthermore, classical features of the procoagulant 
platelet, such as increased membrane permeability8, will enable their in vitro identification by quick 
tests utilising low molecular weight cell impermeant dyes such as propidium iodide which label 
DNA and RNA76. Also, the report of GSAO earlier described as a marker of procoagulant platelets 
demonstrates the feasibility of this approach22. Other features such as a strong fibrinogen or 
coagulation factors (FVa, FXa) binding (Fig. 1), can also be used to identify and quantify the 
preponderance of procoagulant platelets in clinical settings, using image based or flow cytometric 
analysis3. Such assessment, when done before major surgical intervention, may provide reliable 
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data to enable the prediction of whether a patient has a tendency to bleed or will be at risk of 
thrombosis. In addition, these data provide a lead for the development of new bedside medical 
devices, for measuring platelet function and with predictive capabilities for bleeding disorders. For 
example, the in vitro formation of BP, BAPS, FIB-CAP, GSAO or COATED platelets was a strong 
correlate of in vivo arterial thrombus formation (Fig. 1).  
 
4.2       Molecular drivers of procoagulant membrane dynamics as new antithrombotic targets 
Newer data provide insight into the molecular mediators and drivers of the platelet procoagulant 
response8,18,34. These molecular mechanisms reveal alternative targets for the regulation of 
thrombosis, which may spare essential secretion and other platelet functions77,78. Since we had 
recently shown that blockade of P2Y1 and P2Y12 does not inhibit platelet procoagulant balloon 
formation or microvesiculation18, there is an opportunity for development of a new class of 
antithrombotics that target platelet procoagulation. For example, carbonic anhydrases 1, 2 and 13 
have been recently identified as new potential anti-thrombotic targets78,79, for which there are 
already inhibitors in clinical use such as the mild diuretic acetazolamide. We have recently shown 
that acetazolamide is a potent antithrombotic in vivo (Fig. 4 and 8,78,79), and has the potential to be 
a genuinely novel approach to the management of thrombotic disease. The signalling pathway 
involved in the antithrombotic actions of acetazolamide might include the regulation of reactive 
oxygen species by carbonic anhydrase enzymes, but at the moment there is no evidence in the 
literature.  However, several reports indicate that carbonic anhydrase inhibitors are also capable 
of blocking water entry via the water channel AQP180-83, and this may also be an important 
mechanism of action. Consistent with this, we have recently show AQP1 to potently regulate 
thrombus formation in vivo77, implicating it as a target for development of novel antithrombotic 
drugs84,85.  
 
Figure 4: Acetazolamide suppresses 
thrombus formation in vivo. Mice were 
administered acetazolamide (7 mg/kg) or 
vehicle by single bolus intravenous injection, 
followed immediately by DyLight 488–
conjugated anti-GPIbβ antibody to label 
platelets. Carotid artery damage was 
achieved by treatment with FeCl3 as 
previously described8. Fluorescently labelled 
platelets adhering at the site of injury could 
then be imaged continuously by intravital 
fluorescence microscopy. Images at frames 
indicated in A correspond to time points indicated in Bi, which shows median fluorescence intensity, quantified by 
using ImageJ. Analysis of the area under the curve for media fluorescence is shown in Bii as interleaved box plots with 
whiskers showing minimum to maximum values, median, and interquartile range. Data analysis was by Wilcoxon 
signed rank test, P<0.05 (*) was considered significant. Scale bar= 500 µm). Data are from 8 pairs of mice. (Reproduced 
with permission from Circulation. 2015; 132:1414-1424). 
 
A major clinical side effect associated with current antithrombotic regimens in the management of 
CVD is the significant bleeding resulting from the use of dual anti-platelet therapy, for example, 
aspirin and P2Y12 blockers usually targeting the inhibition of platelet secretion. This status quo 
therefore demonstrates a need for alternative targets for the control of thrombotic events 
associated with CVD. With the procoagulant response of activated platelets critically reliant on 
morphological transformations, molecular mediators critical to the fluid entry mechanism which 
drive this event provide new approaches or target genes for the control of bleeding and thrombotic 
disorders. Furthermore, this may reveal new molecular mechanisms in diseases associated with 
disorders of haemostasis. It is well established that platelets secrete a plethora of releasates 
essential for the maintenance of vascular integrity and cardiovascular haemostasis86. 
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Consequently, a new antithrombotic approach that spares essential platelet secretion will 
potentially limit or eliminate the well-known side effects of antiplatelet therapies.  
It is rather surprising that 25% or more of patients on antiplatelet drugs go on to suffer an ischaemic 
event87. Controlled trials of aspirin for the long-term secondary prevention of ischaemic events 
reports only a 13% relative reduction in risk of recurrent stroke88,89. Similar low percent reductions 
were reported in studies evaluating the effects of aspirin in the 4-week risk period of recurrent 
stroke or intracerebral haemorrhage after short-term treatment for stroke. Together, these 
indicate that the present ‘secretion-driven’ approach to controlling platelet function in thrombosis 
is not optimal. Also, newer data show that platelets pre-treated with aspirin or from patients 
administered aspirin still showed full procoagulant response upon stimulation22,90 (Fig. 1). The 
heterogeneity of activated platelets comes with unique challenges for drug therapy; aspirin for 
instance, will likely affect only aggregating platelets, which may present as conventional spread, 
non-ballooning platelets (CSNB) on collagen matrix8. Therefore, co-administration of agents like 
acetazolamide that suppress platelet procoagulant responses and thrombus formation by distinct 
mechanisms, may prove effective to limit the procoagulant response of platelets in patients 
already on aspirin. The existing literature suggests a need for such clinically effective antiplatelet-
antiprocoagulant regimen87.  
 
4.3       Potential Challenges of Procoagulant Platelet Inhibition 
Platelet procoagulant activity has been linked to stroke and coronary artery disease71,91,92, however 
this activity is also vital for haemostasis after vessel injury71; thus its blockade as an antithrombotic 
approach may precipitate a bleeding diathesis if not fine-tuned. For example, the bleeding defect 
of Scott patients may be attributable to an aberrant procoagulant activity8,93,94. Also, prolonged 
bleeding times have been reported in TMEM16F null mice which showed a deficiency in Ca2+-
dependent PS exposure and procoagulant activity in platelets53,55. Fine tuning of therapy may 
therefore be required. Targeting platelet aquaporins however may achieve this fine tuning, since 
we have recently shown that mice lacking AQP1 show normal haemostasis whereas thrombus 
formation was significantly attenuated77. In addition, it may be possible to envisage the use of 
lower dose acetazolamide in combination with lower dose aspirin, thereby achieving 
antithrombotic activity at doses lower than currently recognised to cause their clinical adverse 
effects.  
 
Conclusion 
The major platelet phenotypes identified over the last 40 years, to support coagulation are 
essentially a versatile subpopulation of activated platelets, which we now suggest be referred to 
as procoagulant platelets. Procoagulant platelets undergo morphological transformations which 
amplify the surface area required for phosphatidylserine exposure and the acceleration of 
coagulation. Molecular drivers of procoagulant membrane dynamics provide distinct targets for 
the regulation of procoagulant platelets’ role in thrombosis. Targeting the water channel AQP1 or 
carbonic anhydrase enzymes may therefore represent novel approaches in the management of 
thrombotic disease, both arterial and venous, with potential to suppress the function of 
procoagulant platelets and selectively limit thrombosis with minimal effect on other platelet 
functions. 
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